Dysesthesia associated with GLP-1 agonist therapies- data-mining analysis
A study reveals that GLP-1 agonists like semaglutide are linked to significant signals for hyperesthesia, dysesthesia, and burning sensation. These reactions are dose-dependent and can recur upon rechallenge.
GLP-1 agonists in addiction therapy – review
GLP-1 receptor agonists show promise in reducing alcohol consumption and cravings, as well as supporting nicotine abstinence. However, more research is needed for stimulant use disorders.
Real-World Cardiovascular Outcomes of ObesityTreatment With Tirzepatide Versus Semaglutide
Tirzepatide significantly reduces new-onset heart failure risk compared to semaglutide in obese, non-diabetic adults over 12 months
GLP-1 Drugs Reshape Food Markets: Tapatío Sales Surge
GLP-1 receptor agonist benefits include appetite regulation and shifts in food preferences. Patients on these drugs often seek stronger flavors to enhance smaller meals. This trend is reflected in the surge of Tapatío hot sauce sales.
How GLP-1 Weight Loss Drug Economics Reshape US Food Industry
GLP-1 weight loss drug economics are driving significant changes in the US food industry. These drugs influence patient dietary habits, leading to shifts in agricultural demand and food manufacturing. Understanding these economic impacts helps clinicians…
Cannabis Doctor Investigates THC and Peptides Like Semaglutide
This article explores polypharmacy metabolic health with a focus on THC and peptides like semaglutide. The study aims to understand potential drug interactions and clinical outcomes. Polypharmacy metabolic health is critical for safe cannabis medicine…
Exploring GLP-1 Receptor Agonists for Addiction Treatment
GLP-1 receptor agonists addiction benefits are emerging as a promising area in addiction medicine. These medications may reduce cravings and addictive behaviors by modulating brain reward pathways. Research continues to explore their potential beyond…